ImmunoGen Appoints Tracey L. McCain, Esq. to Its Board of Directors
November 17 2021 - 4:01PM
Business Wire
ImmunoGen Inc. (Nasdaq: IMGN), a leader in the expanding field
of antibody-drug conjugates (ADCs) for the treatment of cancer,
today announced the appointment of Tracey L. McCain, Esq. to its
Board of Directors.
“We are thrilled to have Tracey join ImmunoGen’s Board of
Directors at this critical juncture for the Company,” said Stephen
McCluski, ImmunoGen’s Chairman of the Board of Directors. “As
ImmunoGen awaits top-line data from the pivotal SORAYA trial for
mirvetuximab soravtansine in ovarian cancer this quarter, continues
to advance its pipeline, and prepares for potential
commercialization next year, Tracey’s impressive legal background
supporting a variety of corporate initiatives will be instrumental
to the Board and management team in ensuring the Company continues
to have best-in-class governance and compliance measures in
place.”
Ms. McCain has more than 20 years of legal, management, and
transactional experience in the biopharmaceutical industry and
currently serves as the Executive Vice President and Chief Legal
and Compliance Officer at Blueprint Medicines Corporation. Prior to
joining Blueprint, she served as Senior Vice President and Head of
Legal for Sanofi Genzyme, was a member of the executive leadership
team, and a member of the leadership team for Sanofi’s global legal
department. Prior to that, Ms. McCain served as Genzyme’s general
counsel after it was acquired by Sanofi in 2011. In her capacity as
Genzyme’s general counsel, Ms. McCain was responsible for all
aspects of its legal department in the U.S. and throughout Europe,
including general corporate, commercial and intellectual property
matters, and support of business development initiatives. Prior to
Genzyme’s acquisition, Ms. McCain was also responsible for managing
the securities and employment law teams and support of non-patent
litigation. Before Genzyme, Ms. McCain was an associate at the law
firm Palmer & Dodge LLP. She received her B.A. from the
University of Pennsylvania and her J.D. from Columbia University
School of Law.
Ms. McCain stated, “I’m excited to join ImmunoGen’s Board during
this pivotal time, as the Company approaches an important clinical
readout, while simultaneously progressing the rest of its pipeline
of novel ADCs. I look forward to offering my expertise and working
with ImmunoGen’s leadership as the Company looks to transition into
a fully integrated oncology company next year.”
ABOUT IMMUNOGEN
ImmunoGen is developing the next generation of antibody-drug
conjugates (ADCs) to improve outcomes for cancer patients. By
generating targeted therapies with enhanced anti-tumor activity and
favorable tolerability profiles, we aim to disrupt the progression
of cancer and offer our patients more good days. We call this our
commitment to TARGET A BETTER NOW™.
Learn more about who we are, what we do, and how we do it at
www.immunogen.com.
FORWARD-LOOKING STATEMENTS
This press release includes forward-looking statements based on
management’s current expectations. These statements include, but
are not limited to, ImmunoGen’s expectations related to: the
occurrence, timing, and outcome of potential preclinical, clinical,
and regulatory events related to the Company’s product candidates,
in particular with respect to mirvetuximab soravtansine and
IMGN632, and the launch of those product candidates next year; and
the presentation of preclinical and clinical data on the Company’s
product candidates, including with respect to mirvetuximab
soravtansine and IMGN632. For these statements, ImmunoGen claims
the protection of the safe harbor for forward-looking statements
provided by the Private Securities Litigation Reform Act of 1995.
Various factors could cause ImmunoGen’s actual results to differ
materially from those discussed or implied in the forward-looking
statements, and you are cautioned not to place undue reliance on
these forward-looking statements, which are current only as of the
date of this release. Factors that could cause future results to
differ materially from such expectations include, but are not
limited to: the timing and outcome of the Company’s preclinical and
clinical development processes; the difficulties inherent in the
development of novel pharmaceuticals, including uncertainties as to
the timing, expense, and results of preclinical studies, clinical
trials, and regulatory processes; the Company’s ability to
financially support its product programs; risks and uncertainties
associated with the scale and duration of the COVID-19 pandemic and
the resulting impact on ImmunoGen’s industry and business; and
other factors as set forth in the Company’s Annual Report on Form
10-K filed with the Securities and Exchange Commission on March 1,
2021, and other reports filed with the Securities and Exchange
Commission.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20211117005358/en/
INVESTOR RELATIONS AND MEDIA CONTACTS ImmunoGen Courtney
O’Konek 781-895-0600 courtney.okonek@immunogen.com OR FTI
Consulting Robert Stanislaro 212-850-5657
robert.stanislaro@fticonsulting.com
ImmunoGen (NASDAQ:IMGN)
Historical Stock Chart
From Apr 2024 to May 2024
ImmunoGen (NASDAQ:IMGN)
Historical Stock Chart
From May 2023 to May 2024